Skip to content
cefepime

Structure via PubChem · Public domain (PubChem)

EntityQ2552927· pop 27· linked from 214 articles

Also known as (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, BMY-28142, Maxipime, Cefepima, Cefepimum, CFPM

Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other β-lactam antibiotics. In response, the U.S. Food and Drug Administration (FDA) performed their own meta-analysis which found no mortality difference.

Chemical data

Formula
C19H24N6O5S2
Molecular weight
480.6 g/mol
IUPAC name
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
SMILES
C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
InChIKey
HVFLCNVBZFFHBT-ZKDACBOMSA-N
XLogP
-0.1
Polar surface area
204 Ų
H-bond donors
2
H-bond acceptors
10
Formal charge
0

via PubChem

Research

5,633 papers

via PubMed

Wikidata facts

Mass
480.12496
Show 6 more facts
chemical formula
C₁₉H₂₄N₆O₅S₂
defined daily dose
2
isomeric SMILES
C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
canonical SMILES
C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-]
World Health Organisation international non-proprietary name
cefepime
Commons category
Cefepime
Sources (8)

via Wikidata · CC0

~3 min read

Article

7 sections
Contents
  • Medical use
  • Spectrum of bacterial susceptibility
  • Cefepime induced neurotoxicity
  • Chemistry
  • Trade names
  • References
  • External links

Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other β-lactam antibiotics. In response, the U.S. Food and Drug Administration (FDA) performed their own meta-analysis which found no mortality difference.

Cefepime was patented in 1982 by Bristol-Myers Squibb and approved for medical use in 1994. It is available as a generic drug and sold under a variety of trade names worldwide.

Connections

Categories